Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

STA-BX909: a promising new agent for BNCT

Aug. 17, 1999

K-252a derivatives with potential application in cancer and neurologic disorders

Aug. 17, 1999

Oxigene licenses combretastatin prodrug from Arizona State University

Aug. 17, 1999

Gliadel Wafer approved in Germany for recurrent GBM

Aug. 17, 1999

Evacet/Taxotere combination therapy to be assessed in metastatic breast cancer

Aug. 17, 1999

Antiangiogenic drug ZD-4190 excels in preclinical testing at AstraZeneca

Aug. 16, 1999

Tyrosine kinase inhibitors potentially useful for patient-specific treatment of tumors

Aug. 16, 1999

ImClone Systems initiates phase II C225/cisplatin trial

Aug. 16, 1999

Temodar gets accelerated approval in U.S.; first new drug in 20 years for anaplastic astrocytoma

Aug. 13, 1999

Schering-Plough continues research into protein farnesyltransferase inhibitors

Aug. 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...